-1.80%
30.46%
20.16%
84.84%
17.06%
-39.26%
2.49%
AI Spotlight on ATRC
Company Description
AtriCure, Inc.develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.
It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes.In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves.It markets and sells its products through independent distributors and direct sales personnel.
The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Market Data
| Last Price | 39.87 |
| Change Percentage | -1.80% |
| Open | 40.71 |
| Previous Close | 40.6 |
| Market Cap ( Millions) | 1944 |
| Volume | 398927 |
| Year High | 43.11 |
| Year Low | 18.94 |
| M A 50 | 34.7 |
| M A 200 | 27.55 |
Financial Ratios
| FCF Yield | -0.06% |
| Dividend Yield | 0.00% |
| ROE | -8.42% |
| Debt / Equity | 16.59% |
| Net Debt / EBIDTA | 410.93% |
| Price To Book | 4.04 |
| Price Earnings Ratio | -48.26 |
| Price To FCF | -1684.4 |
| Price To sales | 4.34 |
| EV / EBITDA | -146.01 |
News
- Oct -30 - AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
- Oct -30 - AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Oct -29 - AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
- Oct -16 - AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
- Oct -11 - AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
- Sep -05 - Faisal Al Bannai
- Aug -28 - AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
- Aug -23 - AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
- Jul -31 - AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
- Jul -30 - AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
- Jul -30 - AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
- Jul -24 - AtriCure (ATRC) Gains China Approval for AtriClip LAA System
- Jun -28 - Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
- May -02 - AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
- May -02 - Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
- May -01 - AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
- May -01 - AtriCure Reports First Quarter 2024 Financial Results
- Apr -19 - AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
- Feb -16 - AtriCure, Inc. (ATRC) Q4 2023 Earnings Call Transcript
- Feb -16 - Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Appendage Management
Expected Growth : 12 %
What the company do ?
AtriCure's Appendage Management system is a minimally invasive procedure for left atrial appendage closure, reducing stroke risk in AFib patients.
Why we expect these perspectives ?
AtriCure's Appendage Management segment growth is driven by increasing adoption of its LARIAT device, expanding indications for left atrial appendage closure, and rising awareness of stroke risk reduction. Additionally, strategic partnerships, investments in clinical trials, and growing demand for minimally invasive procedures contribute to the 12% growth rate.
Segment n°2 -> Open Ablation
Expected Growth : 13 %
What the company do ?
Open Ablation from AtriCure, Inc. is a minimally invasive surgical procedure that treats atrial fibrillation by isolating the pulmonary veins.
Why we expect these perspectives ?
Open Ablation's 13% growth driven by increasing adoption in atrial fibrillation treatment, expanding indications for persistent and long-standing persistent AF, and growing demand for minimally invasive procedures. Additionally, AtriCure's strategic partnerships, investments in clinical trials, and sales force expansion contribute to the segment's growth.
Segment n°3 -> Minimally Invasive Ablation
Expected Growth : 14 %
What the company do ?
Minimally Invasive Ablation from AtriCure, Inc. is a surgical procedure that treats atrial fibrillation using a minimally invasive approach to isolate and ablate abnormal electrical pathways.
Why we expect these perspectives ?
Strong demand for minimally invasive procedures, increasing adoption of AtriCure's Synergy Ablation System, and expanding indications for atrial fibrillation treatment drive 14% growth. Additionally, investments in clinical trials, sales force expansion, and strategic partnerships contribute to the company's rapid growth.
Segment n°4 -> Pain Management
Expected Growth : 11 %
What the company do ?
AtriCure's Pain Management system is a minimally invasive procedure that uses radiofrequency ablation to treat chronic pain in the spine and joints.
Why we expect these perspectives ?
AtriCure's Pain Management segment growth is driven by increasing adoption of minimally invasive procedures, rising demand for alternative treatments to opioids, and expanding indications for ablation therapies. Additionally, the company's investments in clinical trials, product innovation, and strategic partnerships are contributing to its 11% growth.
Atricure, Inc. Products
| Product Range | What is it ? |
|---|---|
| Isolator Synergy Ablation System | A minimally invasive cardiac ablation system designed to treat atrial fibrillation and other cardiac arrhythmias. |
| EPi-Sense System | A system that provides real-time feedback during cardiac ablation procedures to help physicians identify and treat abnormal heart rhythms. |
| Synergy Ablation System | A cardiac ablation system that uses radiofrequency energy to create lesions in the heart tissue to block abnormal electrical signals. |
| Cryo1 Cryoablation System | A cryoablation system that uses extremely cold temperatures to freeze and destroy abnormal heart tissue. |
| Hybrid AF Solution | A comprehensive solution that combines minimally invasive surgical and catheter-based ablation procedures to treat atrial fibrillation. |
AtriCure, Inc.'s Porter Forces
Threat Of Substitutes
AtriCure, Inc. faces moderate threat from substitutes due to the presence of alternative treatments for atrial fibrillation, such as medications and catheter ablation. However, the company's minimally invasive surgical ablation technology provides a unique solution that is less invasive and more effective than traditional surgical methods.
Bargaining Power Of Customers
AtriCure, Inc. has a diverse customer base, including hospitals and medical centers, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized and critical to patient care, making it difficult for customers to negotiate prices.
Bargaining Power Of Suppliers
AtriCure, Inc. has a diversified supply chain and is not heavily dependent on a single supplier. The company also has a strong track record of developing and manufacturing its own products, reducing its reliance on external suppliers.
Threat Of New Entrants
The medical device industry is highly regulated, and new entrants would need to invest heavily in research and development, clinical trials, and regulatory approvals to enter the market. AtriCure, Inc.'s established brand and intellectual property also create barriers to entry.
Intensity Of Rivalry
The medical device industry is highly competitive, with several established players competing for market share. However, AtriCure, Inc.'s focus on atrial fibrillation and its minimally invasive surgical ablation technology differentiate it from competitors and reduce the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 11.93% |
| Debt Cost | 9.12% |
| Equity Weight | 88.07% |
| Equity Cost | 10.99% |
| WACC | 10.77% |
| Leverage | 13.54% |
AtriCure, Inc. : Quality Control
AtriCure, Inc. passed 7 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| SMTI | Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen … |
| WRBY | Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and … |
| RVP | Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and … |
| STXS | Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the … |
| DXR | Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Daxor
A-Score
1-Year Total Return ->
🥈
Retractable Technologies
A-Score
1-Year Total Return ->
🥉
Warby Parker
A-Score
1-Year Total Return ->
4
Stereotaxis
A-Score
1-Year Total Return ->
5
Sanara MedTech
A-Score
1-Year Total Return ->
6
